IL318777A - Heterocyclic compounds, compositions thereof, and methods of treatment therewith - Google Patents

Heterocyclic compounds, compositions thereof, and methods of treatment therewith

Info

Publication number
IL318777A
IL318777A IL318777A IL31877725A IL318777A IL 318777 A IL318777 A IL 318777A IL 318777 A IL318777 A IL 318777A IL 31877725 A IL31877725 A IL 31877725A IL 318777 A IL318777 A IL 318777A
Authority
IL
Israel
Prior art keywords
compositions
methods
heterocyclic compounds
treatment therewith
therewith
Prior art date
Application number
IL318777A
Other languages
Hebrew (he)
Inventor
Chao Yu
Jie Chen
Yichao Bian
Xiaoyu Li
Hanzi Sun
Huaqing Liu
Ce Wang
Zhiwei Wang
Original Assignee
Beigene Switzerland Gmbh
Chao Yu
Jie Chen
Yichao Bian
Xiaoyu Li
Hanzi Sun
Huaqing Liu
Ce Wang
Zhiwei Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland Gmbh, Chao Yu, Jie Chen, Yichao Bian, Xiaoyu Li, Hanzi Sun, Huaqing Liu, Ce Wang, Zhiwei Wang filed Critical Beigene Switzerland Gmbh
Publication of IL318777A publication Critical patent/IL318777A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL318777A 2022-08-11 2023-08-10 Heterocyclic compounds, compositions thereof, and methods of treatment therewith IL318777A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2022111871 2022-08-11
CN2022121125 2022-09-23
CN2023079087 2023-03-01
CN2023093212 2023-05-10
PCT/CN2023/112168 WO2024032702A1 (en) 2022-08-11 2023-08-10 Heterocyclic compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
IL318777A true IL318777A (en) 2025-04-01

Family

ID=89850951

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318777A IL318777A (en) 2022-08-11 2023-08-10 Heterocyclic compounds, compositions thereof, and methods of treatment therewith

Country Status (14)

Country Link
US (1) US20240262848A1 (en)
EP (1) EP4568974A4 (en)
JP (1) JP2025528147A (en)
KR (1) KR20250047379A (en)
CN (2) CN121537411A (en)
AR (1) AR130165A1 (en)
AU (1) AU2023320914A1 (en)
CA (1) CA3264226A1 (en)
CL (1) CL2025000363A1 (en)
CO (1) CO2025002940A2 (en)
IL (1) IL318777A (en)
MX (1) MX2025001680A (en)
TW (1) TW202417454A (en)
WO (1) WO2024032702A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172737A1 (en) 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN121487738A (en) 2023-03-30 2026-02-06 锐新医药公司 Compositions for inducing RAS GTP hydrolysis and their uses
KR20260019479A (en) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Combination therapy for RAS-related diseases or disorders
CN121194980A (en) * 2023-05-16 2025-12-23 和记黄埔医药(上海)有限公司 Tricyclic compounds and their uses
EP4724445A1 (en) 2023-06-06 2026-04-15 Kumquat Biosciences Inc. Substituted heterocycles and uses thereof
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
EP4735451A1 (en) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
CN121889155A (en) 2023-08-07 2026-04-17 锐新医药公司 RMC-6291 for the treatment of RAS protein-related diseases or disorders
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
US20250163079A1 (en) * 2023-11-01 2025-05-22 Incyte Corporation Kras inhibitors
TW202539672A (en) * 2024-02-06 2025-10-16 大陸商上海齊魯製藥研究中心有限公司 Pyrimidine macrocyclic KRAS inhibitors
WO2025168072A1 (en) * 2024-02-08 2025-08-14 Beigene (Suzhou) Co., Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
TW202615036A (en) * 2024-07-31 2026-04-16 大陸商和記黃埔醫藥(上海)有限公司 Tricyclic compounds and uses thereof
TW202615038A (en) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026098684A1 (en) * 2024-11-11 2026-05-15 上海科州药物股份有限公司 Heterocyclic compound as kras inhibitor, preparation therefor and therapeutic use thereof
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
CN114615981B (en) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 KRAS G12D inhibitors
CN112574224A (en) * 2019-09-30 2021-03-30 上海迪诺医药科技有限公司 KRAS G12C inhibitor and application thereof
WO2022170999A1 (en) * 2021-02-09 2022-08-18 南京明德新药研发有限公司 Pyridine[4,3-d]pyrimidine compound
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CA3215949A1 (en) * 2021-04-08 2022-10-13 Genentech, Inc. Oxazepine compounds and uses thereof in the treatment of cancer
WO2023172737A1 (en) * 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
KR20250034087A (en) * 2022-07-09 2025-03-10 블로썸힐 테라퓨틱스, 인크. Fusion-Ring KRAS Inhibitors for Disease Treatment
AU2023320565A1 (en) * 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
CO2025002940A2 (en) 2025-03-27
EP4568974A4 (en) 2026-05-20
CN119677754A (en) 2025-03-21
CL2025000363A1 (en) 2025-06-06
JP2025528147A (en) 2025-08-26
TW202417454A (en) 2024-05-01
AU2023320914A1 (en) 2025-02-27
MX2025001680A (en) 2025-05-02
CA3264226A1 (en) 2024-02-15
US20240262848A1 (en) 2024-08-08
EP4568974A1 (en) 2025-06-18
AR130165A1 (en) 2024-11-13
WO2024032702A1 (en) 2024-02-15
KR20250047379A (en) 2025-04-03
CN121537411A (en) 2026-02-17

Similar Documents

Publication Publication Date Title
CA3264226A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
IL288278A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
EP4171568A4 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
IL315099A (en) Heterocyclic compounds and uses thereof
EP4110369A4 (en) Methods of treatment and related compositions
IL312583A (en) Composition for treatment and prevention of covid-19
EP4003246A4 (en) Compositions and methods for treatment of presbyopia
IL291548A (en) Pediatric trazodone compositions and method of treatment thereof
ZA202007320B (en) Compounds for pain treatment, compositions comprising same, and methods of using same
IL314594A (en) Heterocyclic compounds and methods of use
IL288415A (en) Compositions and methods for treatment of hemochromatosis
EP4003341A4 (en) Compositions and methods for treatment of presbyopia
HK40124853A (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
GB2607584B (en) Composition and method of treatment
GB202212451D0 (en) Methods and compositions for the treatment of hemangioma
HK40104701A (en) Compounds, compositions and methods of treatment thereof
GB2595502B (en) Compounds, compositions and methods for the treatment or prevention of hair loss
SI4334289T1 (en) Novel heterocyclic compounds, compositions, methods of preparation and uses thereof
HK40117615A (en) Compositions and methods for treatment of epilepsies
GB202016159D0 (en) Compound, compositions and methods for the treatment of pain
EP4359404A4 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
EP4359406A4 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091354A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40068676A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
IL305890A (en) Compositions and Methods for the Treatment of Alopecia